Hyperlipidemia is a well-documented risk factor for cardiovascular disease (CVD). Current treatment guidelines for hyperlipidemia are based on the National Cholesterol Education Program's Adult Treatment Program-III (ATP-III) recommendations. Statins are the preferred class of drugs for lowering low-density lipoprotein cholesterol (LDL-C). Other options include ezetimibe, fibrates, niacin, and dietary supplements. Recent research has raised questions about the aggressiveness of ATP-III guidelines, with new ATP-IV guidelines expected soon. Physicians currently face uncertainty about LDL-C targets, whether to treat high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels, and how to achieve target goals. Hyperlipidemia refers to elevated cholesterol, triglycerides, or both. It can be genetic or acquired. Primary care providers should recognize the major categories of dyslipidemia and know when to refer to a lipidologist. The paper reviews the categories of hyperlipidemia, current treatment recommendations, and unresolved questions. Hyperlipidemia is classified based on lipoprotein abnormalities. It can be isolated cholesterol elevation, isolated triglyceride elevation, or both. Genetic and secondary causes are important to consider. Secondary causes include hypothyroidism, diabetes, renal disease, and alcoholism. Cardiovascular risk assessment is crucial in interpreting lipid screening results. Tools like the Framingham Risk Score are used, though they have limitations. Non-HDL cholesterol and apolipoprotein B are emerging markers for CVD risk. However, their clinical utility is still debated. Treatment goals for hyperlipidemia are outlined in ATP-III guidelines. Statins are first-line therapy, with alternatives available for those intolerant or who fail to achieve goals. Lifestyle changes, including diet, weight loss, and exercise, are recommended as initial steps. Statins are the preferred treatment, with atorvastatin and rosuvastatin being the most effective. Alternatives include ezetimibe, fibrates, niacin, and dietary supplements. Complementary products like garlic, artichoke leaf extract, and red yeast rice may offer modest lipid-lowering effects but lack strong evidence for CVD reduction. Controversies remain regarding LDL-C targets, the role of HDL-C, and the effectiveness of non-statin therapies. Residual risk remains a challenge, with some advocating for non-traditional biomarkers. However, evidence is limited, and the role of these markers is still unclear. Current guidelines emphasize aggressive lipid management for high-risk patients. Ongoing research aims to refine treatment strategies and improve outcomes. The paper highlights the importance of individualized care, balancing risk and benefit for each patient.Hyperlipidemia is a well-documented risk factor for cardiovascular disease (CVD). Current treatment guidelines for hyperlipidemia are based on the National Cholesterol Education Program's Adult Treatment Program-III (ATP-III) recommendations. Statins are the preferred class of drugs for lowering low-density lipoprotein cholesterol (LDL-C). Other options include ezetimibe, fibrates, niacin, and dietary supplements. Recent research has raised questions about the aggressiveness of ATP-III guidelines, with new ATP-IV guidelines expected soon. Physicians currently face uncertainty about LDL-C targets, whether to treat high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels, and how to achieve target goals. Hyperlipidemia refers to elevated cholesterol, triglycerides, or both. It can be genetic or acquired. Primary care providers should recognize the major categories of dyslipidemia and know when to refer to a lipidologist. The paper reviews the categories of hyperlipidemia, current treatment recommendations, and unresolved questions. Hyperlipidemia is classified based on lipoprotein abnormalities. It can be isolated cholesterol elevation, isolated triglyceride elevation, or both. Genetic and secondary causes are important to consider. Secondary causes include hypothyroidism, diabetes, renal disease, and alcoholism. Cardiovascular risk assessment is crucial in interpreting lipid screening results. Tools like the Framingham Risk Score are used, though they have limitations. Non-HDL cholesterol and apolipoprotein B are emerging markers for CVD risk. However, their clinical utility is still debated. Treatment goals for hyperlipidemia are outlined in ATP-III guidelines. Statins are first-line therapy, with alternatives available for those intolerant or who fail to achieve goals. Lifestyle changes, including diet, weight loss, and exercise, are recommended as initial steps. Statins are the preferred treatment, with atorvastatin and rosuvastatin being the most effective. Alternatives include ezetimibe, fibrates, niacin, and dietary supplements. Complementary products like garlic, artichoke leaf extract, and red yeast rice may offer modest lipid-lowering effects but lack strong evidence for CVD reduction. Controversies remain regarding LDL-C targets, the role of HDL-C, and the effectiveness of non-statin therapies. Residual risk remains a challenge, with some advocating for non-traditional biomarkers. However, evidence is limited, and the role of these markers is still unclear. Current guidelines emphasize aggressive lipid management for high-risk patients. Ongoing research aims to refine treatment strategies and improve outcomes. The paper highlights the importance of individualized care, balancing risk and benefit for each patient.